Literature DB >> 27162619

Regulation and function of miR-214 in pulmonary arterial hypertension.

Hannah C Stevens1, Lin Deng1, Jennifer S Grant2, Karine Pinel1, Matthew Thomas3, Nicholas W Morrell4, Margaret R MacLean5, Andrew H Baker6, Laura Denby6.   

Abstract

Dysregulation of microRNAs (miRNAs) can contribute to the etiology of diseases, including pulmonary arterial hypertension (PAH). Here we investigated a potential role for the miR-214 stem loop miRNA and the closely linked miR-199a miRNAs in PAH. All 4 miRNAs were upregulated in the lung and right ventricle (RV) in mice and rats exposed to the Sugen (SU) 5416 hypoxia model of PAH. Further, expression of the miRNAs was increased in pulmonary artery smooth muscle cells exposed to transforming growth factor β1 but not BMP4. We then examined miR-214(-/-) mice exposed to the SU 5416 hypoxia model of PAH or normoxic conditions and littermate controls. There were no changes in RV systolic pressure or remodeling observed between the miR-214(-/-) and wild-type hypoxic groups. However, we observed a significant increase in RV hypertrophy (RVH) in hypoxic miR-214(-/-) male mice compared with controls. Further, we identified that the validated miR-214 target phosphatase and tensin homolog was upregulated in miR-214(-/-) mice. Thus, miR-214 stem loop loss leads to elevated RVH and may contribute to the heart failure associated with PAH.

Entities:  

Keywords:  Sugen 5416 hypoxia model; microRNA-199; right ventricular hypertrophy; transforming growth factor β1

Year:  2016        PMID: 27162619      PMCID: PMC4860547          DOI: 10.1086/685079

Source DB:  PubMed          Journal:  Pulm Circ        ISSN: 2045-8932            Impact factor:   3.017


  54 in total

1.  Dysregulation of PTEN in cardiopulmonary vascular remodeling induced by pulmonary hypertension.

Authors:  Yazhini Ravi; Karuppaiyah Selvendiran; Sarath Meduru; Lucas Citro; Shan Naidu; Mahmood Khan; Brian K Rivera; Chittoor B Sai-Sudhakar; Periannan Kuppusamy
Journal:  Cell Biochem Biophys       Date:  2013-11       Impact factor: 2.194

2.  miR-21 and miR-214 are consistently modulated during renal injury in rodent models.

Authors:  Laura Denby; Vasudev Ramdas; Martin W McBride; Joe Wang; Hollie Robinson; John McClure; Wendy Crawford; Ruifang Lu; Dianne Z Hillyard; Raya Khanin; Reuven Agami; Anna F Dominiczak; Claire C Sharpe; Andrew H Baker
Journal:  Am J Pathol       Date:  2011-05-31       Impact factor: 4.307

3.  A role for miR-145 in pulmonary arterial hypertension: evidence from mouse models and patient samples.

Authors:  Paola Caruso; Yvonne Dempsie; Hannah C Stevens; Robert A McDonald; Lu Long; Ruifang Lu; Kevin White; Kirsty M Mair; John D McClure; Mark Southwood; Paul Upton; Mei Xin; Eva van Rooij; Eric N Olson; Nicholas W Morrell; Margaret R MacLean; Andrew H Baker
Journal:  Circ Res       Date:  2012-06-19       Impact factor: 17.367

Review 4.  Renal fibrosis: new insights into the pathogenesis and therapeutics.

Authors:  Youhua Liu
Journal:  Kidney Int       Date:  2006-01       Impact factor: 10.612

5.  Rho kinase-mediated vasoconstriction is important in severe occlusive pulmonary arterial hypertension in rats.

Authors:  Masahiko Oka; Noriyuki Homma; Laimute Taraseviciene-Stewart; Kenneth G Morris; Donatas Kraskauskas; Nana Burns; Norbert F Voelkel; Ivan F McMurtry
Journal:  Circ Res       Date:  2007-03-01       Impact factor: 17.367

6.  MiR-214 regulate gastric cancer cell proliferation, migration and invasion by targeting PTEN.

Authors:  Ting-Song Yang; Xiao-Hu Yang; Xu-Dong Wang; Yi-Ling Wang; Bo Zhou; Zhen-Shun Song
Journal:  Cancer Cell Int       Date:  2013-07-08       Impact factor: 5.722

7.  Development of pulmonary arterial hypertension in mice over-expressing S100A4/Mts1 is specific to females.

Authors:  Yvonne Dempsie; Margaret Nilsen; Kevin White; Kirsty M Mair; Lynn Loughlin; Noona Ambartsumian; Marlene Rabinovitch; Margaret R Maclean
Journal:  Respir Res       Date:  2011-12-20

8.  MicroRNA-214 suppresses oncogenesis and exerts impact on prognosis by targeting PDRG1 in bladder cancer.

Authors:  Jinfeng Wang; Xin Zhang; Lili Wang; Yongmei Yang; Zhaogang Dong; Haiyan Wang; Lutao Du; Chuanxin Wang
Journal:  PLoS One       Date:  2015-02-23       Impact factor: 3.240

Review 9.  Pulmonary arterial hypertension: basis of sex differences in incidence and treatment response.

Authors:  K M Mair; A K Z Johansen; A F Wright; E Wallace; M R MacLean
Journal:  Br J Pharmacol       Date:  2014-02       Impact factor: 8.739

10.  The hypoxia-inducible microRNA cluster miR-199a∼214 targets myocardial PPARδ and impairs mitochondrial fatty acid oxidation.

Authors:  Hamid el Azzouzi; Stefanos Leptidis; Ellen Dirkx; Joris Hoeks; Bianca van Bree; Karl Brand; Elizabeth A McClellan; Ella Poels; Judith C Sluimer; Maarten M G van den Hoogenhof; Anne-Sophie Armand; Xiaoke Yin; Sarah Langley; Meriem Bourajjaj; Serve Olieslagers; Jaya Krishnan; Marc Vooijs; Hiroki Kurihara; Andrew Stubbs; Yigal M Pinto; Wilhelm Krek; Manuel Mayr; Paula A da Costa Martins; Patrick Schrauwen; Leon J De Windt
Journal:  Cell Metab       Date:  2013-09-03       Impact factor: 27.287

View more
  16 in total

1.  CrossTalk opposing view: The mouse SuHx model is not a good model of pulmonary arterial hypertension.

Authors:  Sally H Vitali
Journal:  J Physiol       Date:  2018-11-29       Impact factor: 5.182

2.  CrossTalk proposal: The mouse SuHx model is a good model of pulmonary arterial hypertension.

Authors:  Krishna C Penumatsa; Rod R Warburton; Nicholas S Hill; Barry L Fanburg
Journal:  J Physiol       Date:  2018-11-29       Impact factor: 5.182

Review 3.  Sex, Gender, and Sex Hormones in Pulmonary Hypertension and Right Ventricular Failure.

Authors:  James Hester; Corey Ventetuolo; Tim Lahm
Journal:  Compr Physiol       Date:  2019-12-18       Impact factor: 9.090

Review 4.  Critical effects of epigenetic regulation in pulmonary arterial hypertension.

Authors:  Dewei Chen; Wenxiang Gao; Shouxian Wang; Bing Ni; Yuqi Gao
Journal:  Cell Mol Life Sci       Date:  2017-06-01       Impact factor: 9.261

Review 5.  Mitochondrial dysfunction and pulmonary hypertension: cause, effect, or both.

Authors:  Jeffrey D Marshall; Isabel Bazan; Yi Zhang; Wassim H Fares; Patty J Lee
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2018-01-18       Impact factor: 5.464

6.  Up-Regulation of the Long Noncoding RNA X-Inactive-Specific Transcript and the Sex Bias in Pulmonary Arterial Hypertension.

Authors:  Shanshan Qin; Dan Predescu; Brandon Carman; Priyam Patel; Jiwang Chen; Miran Kim; Tim Lahm; Mark Geraci; Sanda A Predescu
Journal:  Am J Pathol       Date:  2021-04-06       Impact factor: 5.770

7.  Inhibition of MicroRNA-214 Alleviates Lung Injury and Inflammation via Increasing FGFR1 Expression in Ventilator-Induced Lung Injury.

Authors:  Kun He; Shuang Han; Li An; Jin Zhang
Journal:  Lung       Date:  2021-01-03       Impact factor: 2.584

Review 8.  Molecular Mechanisms of Pulmonary Vascular Remodeling in Pulmonary Arterial Hypertension.

Authors:  Jane A Leopold; Bradley A Maron
Journal:  Int J Mol Sci       Date:  2016-05-18       Impact factor: 5.923

9.  Overexpression of MicroRNA-340-5p Inhibits Pulmonary Arterial Hypertension Induced by APE by Downregulating IL-1β and IL-6.

Authors:  Minghui Ou; Chuntang Zhang; Jing Chen; Shibo Zhao; Shichao Cui; Jie Tu
Journal:  Mol Ther Nucleic Acids       Date:  2020-05-22       Impact factor: 10.183

10.  T-Cell-Derived miRNA-214 Mediates Perivascular Fibrosis in Hypertension.

Authors:  Mateusz Siedlinski; Laura Denby; Ryszard Nosalski; Eilidh McGinnigle; Michal Nowak; Aurelie Nguyen Dinh Cat; Laura Medina-Ruiz; Marco Cantini; Dominik Skiba; Grzegorz Wilk; Grzegorz Osmenda; Julie Rodor; Manuel Salmeron-Sanchez; Gerard Graham; Pasquale Maffia; Delyth Graham; Andrew H Baker; Tomasz J Guzik
Journal:  Circ Res       Date:  2020-02-17       Impact factor: 17.367

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.